

## Virus Filtration Efficiency Test (VFE) at an Increased Challenge Level GLP Report


Test Article: MicroGard II 190 g/m<sup>2</sup>, Respiratory Filter  
 Purchase Order: 10003754  
 Laboratory Number: 530460  
 Study Received Date: 28 May 2010  
 Test Procedure(s): Standard Test Protocol (STP) Number: STP0010 Rev 03  
 Protocol Detail Sheet (PDS) Number: 201001539 Rev 01

**Summary:** This procedure was performed to evaluate the virus filtration efficiency (VFE) at an increased challenge level of the test article. A challenge level of greater than 10<sup>6</sup> plaque-forming units (PFU) was delivered to each test article to determine filtration efficiency. The aerosol challenge flow rate was maintained at 30 liters per minute (LPM). This test procedure was modified from Nelson Laboratories, Inc., standard VFE procedure in order to employ a more severe challenge than would be expected in normal use. This method was adapted from ASTM F2101. All test method acceptance criteria were met.

**Results:**

Unit Number	Total PFU Recovered	Filtration Efficiency %
1	9.0 x 10 <sup>1</sup>	99.9966
2	3.6 x 10 <sup>1</sup>	99.9986
3	9.9 x 10 <sup>1</sup>	99.9962
4	1.4 x 10 <sup>2</sup>	99.9949
5	2.0 x 10 <sup>2</sup>	99.9924

Challenge Level: 2.6 x 10<sup>6</sup> PFU  
 Mean Particle Size (MPS): 3.2 μm

  
 Study Director Adrienne Sandall, B.S.

  
 Study Completion Date

**Acceptance Criteria:** The mean particle size (MPS) of the challenge aerosol was maintained at  $3.0 \pm 0.3 \mu\text{m}$ . The average percent VFE for the reference material was within the upper and lower control limits established for the VFE test. The VFE challenge level was  $\geq 1 \times 10^6$  PFU/test article when the flow rate is  $\geq 30$  LPM.

**Challenge Procedure:** The stock bacteriophage  $\Phi\text{X174}$  was prepared by inoculation of  $\Phi\text{X174}$  into a log phase culture of *E. coli*. The culture was shaken at  $37 \pm 2^\circ\text{C}$  until bacterial turbidity cleared. The virus stock was centrifuged to remove large cellular debris and then filtered through a  $0.2 \mu\text{m}$  membrane filter to remove remaining host cell debris. The stock culture was stored at  $2-8^\circ\text{C}$ .

The challenge suspension was pumped through a Chicago nebulizer using a peristaltic pump at a controlled flow rate of 30 LPM and a fixed air pressure. The challenge level was adjusted to provide a consistent challenge of at least  $10^6$  PFU per test article.

The aerosol droplets were generated in a glass aerosol chamber and drawn through the test article holder into AGIs in parallel. Each AGI contained 30 mL aliquots of sterile peptone water (PEPW) to collect the aerosol droplets. The challenge was delivered for a 1 minute interval and sampling through the AGIs was conducted for 2 minutes to clear the aerosol chamber. Control runs (no media in test article holder) were performed after every 5-7 test articles to determine the number of viable particles being generated in the challenge aerosol. The MPS of the challenge aerosol was determined using a six-stage Andersen sampler.

The AGI fluid was assayed using standard plaque assay techniques. All plates were incubated at  $37 \pm 2^\circ\text{C}$  for 12-24 hours. The percent VFE was calculated by subtracting the counts of the test article from the average control counts and dividing by the average control counts.

## Quality Assurance Statement

**Compliance Statement:** The test was conducted in accordance with the USFDA (21 CFR Part 58) Regulations.

Activity	Date
Study Initiation	02 Jun 2010
Audit Performed by Quality Assurance	07 Jun 2010
Audit Results Reported to Study Director	09 Jun 2010
Audit Results Reported to Management	09 Jun 2010


Scientists	Title
Todd Hillam	Section Leader
Adrienne Sandall	Study Director

**Data Disposition:** The raw data and final report from this study are archived at NLI or an approved off-site location.

*Katie Swenson*  
Quality Assurance

*14 Jun 2010*  
Date

Lab Number: 530460

	FORM TITLE: <b>PDS Approval Form</b>	PDS NUMBER: 201001539
		PDS REVISION: 1

PREPARED FOR SPONSOR		LABORATORY / CONTRACTOR
CONTACT:	Helmut Scherer	<b>Nelson Laboratories, Inc.</b> P.O. Box 17577 SALT LAKE CITY, UT. 84117-0557 6280 SOUTH REDWOOD ROAD SALT LAKE CITY, UT. 84123-6600 Tel: 801-290-7500 Fax: 801-290-7998 Web Site: www.nelsonlabs.com
COMPANY:	CareFusion Germany 234 GmbH	
EMAIL:	helmut.scherer@CareFusion.com	
PHONE:	+49 931 4972 784	
FAX:	+49 931 4972 62784	

PROTOCOL SPECIFICATIONS			
PARENTAL DOCUMENT:	VFE at an Increased Challenge Level, STP0010, 3		
SECTION:	Aerobiology		
PDS INITIATION DATE:	13-May-2010	EXPIRATION DATE:	13-May-2012
JUSTIFICATION:			
No changes to the Standard Testing Protocol.			
PROTOCOL SPECIFICATIONS:			
Test according to Standard Test Protocol.			
<input type="radio"/> Additional pages attached for protocol specifications <input checked="" type="radio"/> No additional pages needed			

The sponsor is responsible for test/control article characterization.  
 This includes, but is not limited to, identity, strength, purity, and stability.

**\*\*PLEASE SIGN, DATE, & RETURN TO NELSON LABORATORIES\*\***

<b>SPONSOR APPROVAL:</b>	<b>NELSON LABS STUDY DIRECTOR APPROVAL:</b>
*SIGNATURE: <u>H. Scherer</u>	SIGNATURE: <u>Adrienne Sandall</u>
DATE: <u>14. 05. 2010</u>	DATE: <u>02 Jun 2010</u>
PRINT NAME: <u>Helmut Scherer</u>	PRINT NAME: <u>Adrienne Sandall</u>
*SIGNING THIS DOCUMENT SIGNIFIES AN ACCEPTANCE OF THE NELSON LABORATORIES TESTING TERMS AND CONDITIONS AS ATTACHED OR AS LISTED AT <a href="http://WWW.NELSONLABS.COM/PROTOCOLCONDITIONS.JSP">WWW.NELSONLABS.COM/PROTOCOLCONDITIONS.JSP</a>	

<b>FOR OFFICE USE ONLY</b>	See sample submission form	<input checked="" type="checkbox"/> FDA GLP	<input type="checkbox"/> NON-GLP
----------------------------	----------------------------	---	----------------------------------

©2008 by Nelson Laboratories, Inc. All rights reserved. No part of this document shall be reproduced, stored in a retrieval system, or transmitted by any means, electronic, mechanical, or otherwise, without written permission from Nelson Laboratories Inc.

FRM0206 Rev 7.1

OFFICIAL